Sunjic Igor, Shin Doosup, Sunjic Katlynd M, Popat Jesal V, Tran Thanh, Chae Sanders H, Caldeira Christiano C, Strosberg Jonathan R, Sayad Dany
Division of Cardiovascular Sciences, University of South Florida Morsani College of Medicine, Tampa, FL 33606, USA.
These authors contributed equally to this work.
Cardiol Res. 2020 Feb;11(1):56-60. doi: 10.14740/cr986. Epub 2020 Jan 26.
Carcinoid heart disease (CaHD) is a rare condition that has a high impact on the morbidity and mortality of its patients. Once heart failure symptoms develop in the patient with CaHD, cardiac valve surgery is often the only effective treatment. Although atrioventricular block (AVB) is a known postoperative complication of the valve surgery, the incidence of AVB in this population has not been well described.
Comprehensive records were collected retrospectively on consecutive patients with CaHD who underwent a valve surgery at a tertiary medical center from January 2001 to December 2015. We excluded patients with pre-existing permanent pacemaker (PPM).
Nineteen consecutive patients were included in this study and 18 of them underwent at least dual valve (tricuspid and pulmonary valve) replacement surgery. Our 30-day post-surgical mortality was 0%. During the 6-month observation period following the surgery, 31.5% (n = 6) required PPM implantation due to complete AVB. There was no statistical difference in baseline characteristics and electrocardiographic and echocardiographic parameters between the patients who did or did not require PPM placement.
Our study revealed that almost one-third of CaHD patients who underwent a valve replacement surgery developed AVB requiring PPM implantation. Due to high incidence of PPM requirement, we believe that prophylactic placement of an epicardial lead during the valve surgery can be helpful in these patients to reduce serious complication from placement of pacemaker lead on a later date through a prosthetic valve.
类癌性心脏病(CaHD)是一种罕见疾病,对患者的发病率和死亡率有很大影响。一旦CaHD患者出现心力衰竭症状,心脏瓣膜手术通常是唯一有效的治疗方法。虽然房室传导阻滞(AVB)是瓣膜手术已知的术后并发症,但该人群中AVB的发生率尚未得到充分描述。
回顾性收集2001年1月至2015年12月在一家三级医疗中心接受瓣膜手术的连续CaHD患者的综合记录。我们排除了已有永久性起搏器(PPM)的患者。
本研究纳入了19例连续患者,其中18例至少接受了双瓣膜(三尖瓣和肺动脉瓣)置换手术。我们的术后30天死亡率为0%。在术后6个月的观察期内,31.5%(n = 6)因完全性AVB需要植入PPM。需要或不需要植入PPM的患者在基线特征、心电图和超声心动图参数方面没有统计学差异。
我们的研究表明,几乎三分之一接受瓣膜置换手术的CaHD患者发生了需要植入PPM的AVB。由于PPM需求的高发生率,我们认为在瓣膜手术期间预防性放置心外膜导线对这些患者可能有帮助,以减少日后通过人工瓣膜放置起搏器导线引起的严重并发症。